BioNTech SE
SUBSTITUTED IMIDAZOQUINOLINES
Last updated:
Abstract:
The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
Status:
Application
Type:
Utility
Filling date:
1 Feb 2022
Issue date:
21 Jul 2022